CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Helix BioMedix, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Helix BioMedix, Inc.
SUITE 112, 22121 17TH AVE SE
Phone: (425) 402-8400p:425 402-8400 BOTHELL, WA  98021  United States Ticker: HXBMHXBM
This company ceased filing statements with the SEC on 1/2/2013.
Business Summary
Helix BioMedix, Inc. is a peptide discovery and development biopharmaceutical company, which is focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. The Company’s lead drug development candidate, HB4208, is a deoxyribonucleic damage response enzyme for topical treatment of the rare genetic disorder (orphan disease) Xeroderma Pigmentosum (XP). Its intellectual property portfolio offers multiple pathways for commercialization in this area ranging from Rx dermatology to aesthetic dermatology and personal care. It is developing new treatment options for dermatologic conditions which offer the therapeutic effectiveness and safety benefits of its advanced bioactive small molecule technology. It is transforming the treatment of skin conditions by addressing unmet needs in elegant, life-enhancing topical formulations. Its research and development consist of a proprietary library of bioactive peptides based on the body’s innate immunity.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201212/31/2011YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board R S.Beatty 72 12/31/2019 5/1/1999
President, Chief Executive Officer, Director Robin L.Carmichael 65 7/1/2017 10/31/2007
Independent Director John F.Clifford 79 8/1/2007 8/1/2007
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 8 (As of 12/31/2011)
Outstanding Shares: 224,708 (As of 3/31/2022)
Shareholders: 787
Stock Exchange: OTC
Federal Tax Id: 912099117
Fax Number: (425) 806-2999
Email Address: escheer@helixbiomedix.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023